42 research outputs found

    Maternal Fructose Intake Causes Developmental Reprogramming of Hepatic Mitochondrial Catalytic Activity and Lipid Metabolism in Weanling and Young Adult Offspring

    Get PDF
    Excess dietary fructose is a major public health concern, yet little is known about its influence on offspring development and later-life disease when consumed in excess during pregnancy. To determine whether increased maternal fructose intake could have long-term consequences on offspring health, we investigated the effects of 10% w/v fructose water intake during preconception and pregnancy in guinea pigs. Female Dunkin Hartley guinea pigs were fed a control diet (CD) or fructose diet (FD; providing 16% of total daily caloric intake) ad libitum 60 days prior to mating and throughout gestation. Dietary interventions ceased at day of delivery. Offspring were culled at day 21 (D21) (weaning) and at 4 months (4 M) (young adult). Fetal exposure to excess maternal fructose intake significantly increased male and female triglycerides at D21 and 4 M and circulating palmitoleic acid and total omega-7 through day 0 (D0) to 4 M. Proteomic and functional analysis of significantly differentially expressed proteins revealed that FD offspring (D21 and 4 M) had significantly increased mitochondrial metabolic activities of β-oxidation, electron transport chain (ETC) and oxidative phosphorylation and reactive oxygen species production compared to the CD offspring. Western blotting analysis of both FD offspring validated the increased protein abundances of mitochondrial ETC complex II and IV, SREBP-1c and FAS, whereas VDAC1 expression was higher at D21 but lower at 4 M. We provide evidence demonstrating offspring programmed hepatic mitochondrial metabolism and de novo lipogenesis following excess maternal fructose exposure. These underlying asymptomatic programmed pathways may lead to a predisposition to metabolic dysfunction later in life

    Diagnosis and treatment of pancreatic duct disruption or disconnection: an international expert survey and case vignette study

    Get PDF
    Background: Pancreatic duct disruption or disconnection is a potentially severe complication of necrotizing pancreatitis. With no existing treatment guidelines, it is unclear whether there is any consensus among experts in clinical practice. We evaluated current expert opinion regarding the diagnosis and treatment of pancreatic duct disruption and disconnection in an international case vignette study. Methods: An online case vignette survey was sent to 110 international expert pancreatologists. Expert selection was based on publications in the last 5 years and/or participation in development of IAP/APA and ESGE guidelines on acute pancreatitis. Consensus was defined as agreement by at least 75% of the experts. Results: The response rate was 51% (n = 56). Forty-four experts (79%) obtained a MRI/MRCP and 52 experts (93%) measured amylase levels in percutaneous drain fluid to evaluate pancreatic duct integrity. The majority of experts favored endoscopic transluminal drainage for infected (peri)pancreatic necrosis and pancreatic duct disruption (84%, n = 45) or disconnection (88%, n = 43). Consensus was lacking regarding the treatment of patients with persistent percutaneous drain production, and with persistent sterile necrosis. Conclusion: This international survey of experts demonstrates that there are many areas for which no consensus existed, providing clear focus for future investigation

    CT scan in complicated appendicitis diagnosis: a very costly option

    No full text

    Celiac Artery Stenosis: An Underappreciated and Unpleasant Surprise in Patients Undergoing Pancreaticoduodenectomy

    No full text
    Because of the prevalence of CAS, the pancreatic surgeon needs to maintain a high index of suspicion whenever the preoperative imaging shows extensive pancreatic arterial collateralization, or when intraoperative findings show extensive pancreaticoduodenal collateral vessels, an enlarged GDA, or other unusual arterial anatomy. Because PD disrupts or resects these collateral pathways, potentially providing the only arterial supply to the celiac artery distribution, the ability to revascularize a branch of the celiac artery or to maintain certain collateral supply must be readily available in the operative armamentarium. The type of revascularization depends on the cause of CAS-either celiac decompression for external compression or vascular bypass/celiac branch reimplantation for ostial stenosis. Preoperative diagnosis offers the potential for preoperative revascularization through minimally invasive endovascular techniques. Although the need for aggressive revascularization is rare, when needed, it is imperative, and the surgeon needs to be prepared. © 2008 American College of Surgeons

    Primary pancreatic cystic neoplasms of the pancreas revisited. Part IV: Rare cystic neoplasms

    No full text
    Primary pancreatic cystic neoplasms are being recognized with increasing frequency due to modern imaging techniques. In addition to the more common cystic neoplasms - serous cystadenoma, primary mucinous cystic neoplasm, and intraductal papillary mucinous neoplasm - there are many other less common neoplasms that appear as cystic lesions. These cystic neoplasms include solid pseudopapillary neoplasm of the pancreas (the most common rare cystic neoplasm), cystic neuroendocrine neoplasm, cystic degeneration of otherwise solid neoplasms, and then the exceedingly rare cystic acinar cell neoplasm, intraductal tubular neoplasm, angiomatous neoplasm, lymphoepithelial cysts (not true neoplasms), and few others of mesenchymal origin. While quite rare, the pancreatic surgeon should at the least consider these unusual neoplasms in the differential diagnosis of potentially benign or malignant cystic lesions of the pancreas. Moreover, each of these unusual neoplasms has their own natural history/tumor biology and may require a different level of operative aggressiveness to obtain the optimal outcome. © 2011 Elsevier Ltd. All rights reserved

    Peritonitis after Duodenal Stenting

    No full text
    corecore